Aclaris Therapeutics (ACRS) Gross Margin (2017 - 2025)
Historic Gross Margin for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to 83.69%.
- Aclaris Therapeutics' Gross Margin fell 12600.0% to 83.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 85.62%, marking a year-over-year decrease of 40000.0%. This contributed to the annual value of 85.09% for FY2024, which is 39600.0% down from last year.
- Per Aclaris Therapeutics' latest filing, its Gross Margin stood at 83.69% for Q3 2025, which was down 12600.0% from 71.02% recorded in Q2 2025.
- Aclaris Therapeutics' Gross Margin's 5-year high stood at 95.87% during Q4 2023, with a 5-year trough of 20.51% in Q1 2022.
- Its 5-year average for Gross Margin is 62.88%, with a median of 68.04% in 2023.
- Examining YoY changes over the last 5 years, Aclaris Therapeutics' Gross Margin showed a top increase of 652400bps in 2022 and a maximum decrease of -118500bps in 2022.
- Quarter analysis of 5 years shows Aclaris Therapeutics' Gross Margin stood at 23.45% in 2021, then soared by 278bps to 88.69% in 2022, then increased by 8bps to 95.87% in 2023, then fell by -4bps to 92.35% in 2024, then decreased by -9bps to 83.69% in 2025.
- Its Gross Margin stands at 83.69% for Q3 2025, versus 71.02% for Q2 2025 and 65.22% for Q1 2025.